EC
AVTX icon

EntryPoint Capital’s Avalo Therapeutics AVTX Stock Holding History

EntryPoint Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,041
Closed -$449K – 793
2026
Q1 		$449K Buy
+30,041
New +$470K 0.13% 292

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EntryPoint Capital's AVTX Position: Q2 2026 in Review

EntryPoint Capital sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 30,041 shares — an estimated $449K sold.

EntryPoint Capital first reported a position in AVTX in Q1 2026 and held it in 1 quarter. The position peaked at $449K in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • EntryPoint Capital reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 30,041 Avalo Therapeutics shares in Q2 2026, an estimated $449K.
  • EntryPoint Capital first reported a position in Avalo Therapeutics in Q1 2026 and held it in 1 quarter.
  • EntryPoint Capital's Avalo Therapeutics position peaked at $449K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.